Plain-English translation of NCT06589609 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase 1 trial is testing , a new immunotherapy designed to help your body's immune system fight oropharyngeal cancer caused by HPV16 infection. The medication is given in two ways: directly into the tumor and as an injection into muscle. This is one of the earliest stages of testing, so researchers are primarily learning whether this treatment is safe and how your body tolerates it.
HPV-related throat cancer is becoming more common, especially in younger people, and current treatments don't work for everyone. This medication is being developed to offer a new option that specifically targets the HPV16 virus driving this type of cancer, potentially giving patients another tool in their fight against the disease.
You likely qualify if…
You likely don't qualify if…
As a participant, you will receive the medication through two routes: direct injection into your tumor and intramuscular injection. The trial involves regular visits to the clinic for monitoring, blood tests, heart function checks (ECG), and imaging scans to track how your body responds to the treatment. The exact schedule and duration of treatment will be determined by the research team, but you should be prepared for close medical oversight during the study period.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Austria
Phase
Safety & dosing
Sponsor
BlueSky Immunotherapies GmbH
Enrollment target
~12 participants
Started
August 2024
Primary completion
November 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Medical University of Vienna
BlueSky Immunotherapies GmbH
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.